论文部分内容阅读
目的:探讨应用流式细胞仪(FCM)检测胃癌患者外周血免疫指标,以评价胸腺肽α1联合化疗对胃癌患者免疫功能的影响。方法:70例胃癌患者随机分为用药组和对照组。用药组35例采用胸腺肽α1+化疗,对照组35例单用化疗,两组化疗方案相同。胸腺肽α1每次1.6mg,每周2次,连续4周(共8针)。28天为一疗程,共用2个疗程。采用FCM检测两组患者化疗前后外周血CD4、CD8、CD3+CD4+、CD3+CD8+免疫指标。结果:用药组CD4、CD8、CD3+CD4+、CD4/CD8均高于化疗前和对照组化疗后水平,均具有统计学意义(P<0.05)。结论:胸腺肽α1配合化疗能提高患者的免疫功能,用FCM检测外周血免疫指标为临床观察肿瘤患者的免疫状态提供有效的依据。
Objective: To investigate the application of flow cytometry (FCM) in detecting peripheral blood lymphocytes in patients with gastric cancer to evaluate the effect of thymosin α1 combined with chemotherapy on immune function in patients with gastric cancer. Methods: 70 cases of gastric cancer were randomly divided into medication group and control group. Thirty-five patients in the medication group were treated with thymosin α1 + chemotherapy, and 35 patients in the control group were treated with chemotherapy alone. The two chemotherapy regimens were the same. Thymosin α1 1.6mg each time, twice a week for 4 weeks (a total of 8). 28 days for a course of treatment, sharing 2 courses. The levels of CD4, CD8, CD3 + CD4 + and CD3 + CD8 + in peripheral blood of two groups before and after chemotherapy were detected by FCM. Results: The levels of CD4, CD8, CD3 + CD4 + and CD4 / CD8 in the treatment group were significantly higher than those before chemotherapy and in the control group (P <0.05). Conclusion: Thymosin α1 combined with chemotherapy can improve immune function in patients with FCM detection of peripheral immune indicators for the clinical observation of immune status of patients with tumors provide an effective basis.